吉法匹生片的适应症

Gefapixant is the world's first selective P2X3 receptor antagonist, bringing a breakthrough in the treatment of refractory chronic cough. This innovative drug, jointly developed by Merck and Japan's Kyorin Pharmaceuticals, provides a new treatment option for patients who have long been troubled by chronic cough through a unique molecular mechanism.

Indications of Gefapixin Tablets

It has clear therapeutic indications and is mainly targeted at specific types of chronic cough patient groups.

Refractory chronic cough

It is suitable for symptomatic treatment of refractory chronic cough (RCC) in adults. Such patients usually do not respond well to conventional antitussive treatment, and the cough symptoms last for more than 8 weeks and the cause is difficult to identify.

Unexplained chronic cough

It is also effective for patients with unexplained chronic cough (UCC), in whom the specific cause of the cough cannot be determined after a comprehensive examination.

Applicable population characteristics

For adults only, safety and effectiveness for children under 18 years of age have not been established. Clear treatable causes need to be ruled out before use can be considered.

Identification of these indications is critical to precise medication use to ensure that drugs are used in the patient groups most likely to benefit.

Efficacy and role of Gefapisheng tablets

Gefapisheng tablets exert antitussive effect through a unique mechanism of action, and its pharmacological characteristics are worthy of in-depth discussion.

Targeting P2X3 receptors

As a highly selective P2X3 receptor antagonist, it can specifically block P2X3 receptors on the C fibers of the airway vagus nerve and inhibit ATP-mediated excessive activation of the cough reflex.

Regulate the cough reflex

By down-regulating the sensitivity of the cough reflex pathway, the cough frequency and intensity are reduced, while having little effect on the normal protective cough reflex.

Clinical efficacy characteristics

Phase III clinical studies show that a dose of 45 mg twice a day can significantly reduce the number of coughs in 24 hours and improve patients' quality of life. The efficacy usually appears within 2-4 weeks.

Understanding these pharmacological properties and clinical effects will help doctors fully explain the treatment principles and expected effects to patients.

Contraindications of Gefapisheng Tablets

The use of Gefapisheng Tablets in some specific cases may bring serious risks, and the contraindication standards need to be strictly followed.

Absolute contraindications

Contraindicated in patients with severe hepatic insufficiency (Child-Pugh class C). It is contraindicated in pregnant women as animal studies have shown that the drug can cross the placental barrier. It is prohibited for those who are allergic to drug ingredients.

Relative contraindications

Patients with end-stage renal disease should use it with caution. Breastfeeding women should suspend breastfeeding. Not recommended for use by children under 18 years of age.

Special Precautions

Elderly patients need to evaluate renal function. People with a history of allergy to sulfa drugs may be at risk of cross-allergy. Dosage adjustment is required in patients with severe renal impairment.

Strictly grasping these contraindications can significantly reduce the risks of treatment. Gemfapixin tablets are contraindicated in severe hepatic insufficiency (Child-Pugh C class) and pregnant women.